Talks
RJBC 1501 Trial: Clinical Implications
March 17, 2026
RJBC 1501 Trial: Safety Profile
March 17, 2026
RJBC 1501 Trial: Subgroup Analysis
March 17, 2026
RJBC 1501 Trial: Overall Survival
March 17, 2026
MELODY Trial: Clinical Implications
March 17, 2026
RJBC 1501 Trial: Distant Disease-Free Survival
March 17, 2026
MELODY Trial: Anxiety Outcome Results
March 17, 2026
RJBC 1501 Trial: Disease-Free Survival
March 17, 2026
RJBC 1501 Trial: Patient Characteristics
March 17, 2026
MELODY Trial: Study Design & Endpoints
March 17, 2026
RJBC 1501 Trial: Study Design & Endpoints
March 17, 2026
RJBC 1501 Trial: Clinical Background
March 17, 2026
MELODY Trial: Study Overview
March 17, 2026
RJBC 1501 Trial: Study Overview
March 17, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Key Takeaways
March 10, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Nutritional Intake
March 10, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Bloodstream Infections
March 10, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Key Result
March 10, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Population Characteristics
March 10, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Trial Design
March 10, 2026
Liberalized vs Neutropenic Diet Phase III Trial: Overview
March 10, 2026
SunRISe-4: Safety Profile & Next Steps
February 23, 2026
SunRISe-4: Biomarker Data & Strategies
February 23, 2026
SunRISe-4: Recurrence-Free Survival
February 23, 2026
SunRISe-4: Pathologic Response Rates
February 23, 2026
SunRISe-4: Trial Overview
February 23, 2026
IDeate-Lung01: Safety Profile
February 22, 2026
IDeate-Lung01: Brain Metastases & CNS Control
February 21, 2026
IDeate-Lung01: Activity Across Treatment Lines
February 21, 2026
IDeate-Lung01: Rapid Responses & Durability
February 21, 2026
IDeate-Lung01: Trial Overview
February 21, 2026
Residual Disease
February 8, 2026
Sequencing
February 8, 2026
Triple Negative BC
February 8, 2026
Dual HER2 Blockade
February 8, 2026
HER2 Neoadjuvant Response
February 8, 2026
Germline BRCA
February 8, 2026
CDK4/6 Inhibitors
February 8, 2026
Node Positive HR+/HER2-
February 8, 2026
Oncotype
February 8, 2026
HR+/HER2- Endocrine Treatment
February 8, 2026
BREAKWATER trial_10
January 28, 2026
BREAKWATER trial_9
January 28, 2026
BREAKWATER trial_8
January 28, 2026
BREAKWATER trial_7
January 28, 2026
BREAKWATER trial_6
January 28, 2026
BREAKWATER trial_5
January 28, 2026
BREAKWATER trial_4
January 28, 2026
BREAKWATER trial_3
January 28, 2026
BREAKWATER trial_2
January 28, 2026
BREAKWATER trial_1
January 28, 2026
Basics of early breast cancer_10
January 23, 2026
Basics of early breast cancer_9
January 23, 2026
Basics of early breast cancer_8
January 23, 2026
Basics of early breast cancer_7
January 23, 2026
Basics of early breast cancer_6
January 23, 2026
Basics of early breast cancer_5
January 23, 2026
Basics of early breast cancer_4
January 23, 2026
Basics of early breast cancer_3
January 23, 2026
Basics of early breast cancer_2
January 23, 2026
Close button
Why are you reporting this TALK?